San Diego, CA – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.Read All »
Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellularRead All »
Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the-Shelf Products Offering Broad Patient Access Collaboration to Use Engineered Pluripotent Cell Lines to Renewably Generate T-Cell Product Candidates Foundational Intellectual Property Covering PluripotentRead All »
"Adaptive" Natural Killer Cell Therapeutics to be Advanced as Antibody-Mediated Cancer Therapy Genetically-Engineered Induced Pluripotent Stem Cell-derived Natural Killer Cells to be Developed as Off-the-Shelf Targeted Immunotherapy Fate Therapeutics Holds an Exclusive Option to Secure All PatentRead All »
Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer First-of-Kind Product Candidate to be Manufactured from an Engineered Induced Pluripotent Stem Cell Line Intellectual Property Covering Compositions of Novel CD16 andRead All »
Product Candidates to Incorporate Chimeric Antigen Receptor Construct Optimized for NK Cell Persistence and Anti-Tumor Activity Master Pluripotent Cell Lines Engineered with Chimeric Antigen Receptors to be used for Off-the-Shelf Targeted Natural Killer Cell Product Candidates SAN DIEGO, Dec.Read All »
SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for aRead All »
Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, todayRead All »
No Events of Cancer Relapse No ProTmune-related Serious Adverse Events Reported by Investigators SAN DIEGO , March 19, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies forRead All »
SAN DIEGO , May 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the retirement of Amir Nashat , Sc.D., ManagingRead All »
No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Solid Tumors FavorableRead All »
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data Indicate Favorable Safety Profile with Complete Responses in Heavily Pre-treated Patients with AggressiveRead All »
SAN DIEGO, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the closing of its previously announced initial public offering ofRead All »
San Diego, CA and Ottawa, Canada (October 14, 2010) – Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, through its BD Biosciences segment, for the joint development and worldwideRead All »
SAN DIEGO , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closingRead All »
DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.